707 related articles for article (PubMed ID: 21900088)
1. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
[TBL] [Abstract][Full Text] [Related]
2. Andexanet alfa or prothrombin complex concentrate for acute reversal of oral factor Xa inhibitors: monitoring of antidote effects.
Tanaka KA; Levy JH
Br J Anaesth; 2024 Feb; 132(2):215-217. PubMed ID: 38071150
[TBL] [Abstract][Full Text] [Related]
3. Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series.
Schultz NH; Lundblad R; Holme PA
J Med Case Rep; 2018 May; 12(1):138. PubMed ID: 29764497
[TBL] [Abstract][Full Text] [Related]
4. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.
Liesenfeld KH; Schäfer HG; Trocóniz IF; Tillmann C; Eriksson BI; Stangier J
Br J Clin Pharmacol; 2006 Nov; 62(5):527-37. PubMed ID: 17061960
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs.
Fadraersada J; Alva-Gallegos R; Skořepa P; Musil F; Javorská L; Matoušová K; Krčmová LK; Paclíková M; Carazo A; Blaha V; Mladěnka P
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; 397(6):4461-4470. PubMed ID: 38112731
[TBL] [Abstract][Full Text] [Related]
6. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro.
Schultz NH; Tran HTT; Bjørnsen S; Henriksson CE; Sandset PM; Holme PA
Res Pract Thromb Haemost; 2017 Jul; 1(1):49-56. PubMed ID: 30046673
[TBL] [Abstract][Full Text] [Related]
7. Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.
Bavalia R; Abdoellakhan R; Brinkman HJM; Brekelmans MPA; Hamulyák EN; Zuurveld M; Hutten BA; Westerweel PE; Olie RH; Ten Cate H; Kruip M; Middeldorp S; Meijer K; Coppens M
Res Pract Thromb Haemost; 2020 May; 4(4):569-581. PubMed ID: 32548555
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of the effect of rivaroxaban in sickle cell anemia.
Ataga KI; Elsherif L; Wichlan D; Wogu AF; Matsui N; Pawlinski R; Cai J; Key NS
Transfusion; 2021 Jun; 61(6):1694-1698. PubMed ID: 33660875
[TBL] [Abstract][Full Text] [Related]
9. First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa.
Wu S; Wang T; Li J; Zhang Z; Li C; Xiao S; He J; Wang X; Hu Z; Wang X; Zheng S; Liang X; Chen G; Li Y; Li X; Zhan Y; Zou Q; Jiang H; Zheng Q; Ban L; Liu H; Fang Y
Expert Opin Investig Drugs; 2023; 32(11):1085-1094. PubMed ID: 37955047
[TBL] [Abstract][Full Text] [Related]
10. The Acute Effect of Chamomile Intake on Blood Coagulation Tests in Healthy Volunteers: A Randomized Trial.
Kimura R; Schwartz JA; Romeiser JL; Senzel L; Galanakis D; Halper D; Bennett-Guerrero E
J Appl Lab Med; 2024 May; 9(3):468-476. PubMed ID: 38300838
[TBL] [Abstract][Full Text] [Related]
11. The discovery of rivaroxaban: translating preclinical assessments into clinical practice.
Kubitza D; Perzborn E; Berkowitz SD
Front Pharmacol; 2013 Nov; 4():145. PubMed ID: 24324436
[TBL] [Abstract][Full Text] [Related]
12. The fibrinogen prothrombin time-derived method is not useful in patients anticoagulated with low molecular weight heparins or rivaroxaban.
Duboscq C; Martinuzzo ME; Ceresetto J; Lopez M; Barrera L; Oyhamburu J; Stemmelin G
J Thromb Haemost; 2018 May; ():. PubMed ID: 29790645
[TBL] [Abstract][Full Text] [Related]
13. Prothrombin complex concentrates: an update.
Franchini M; Lippi G
Blood Transfus; 2010 Jul; 8(3):149-54. PubMed ID: 20671873
[No Abstract] [Full Text] [Related]
14. Use of four-factor prothrombin complex concentrate for the mitigation of rivaroxaban-induced bleeding in an emergent coronary artery bypass graft.
Liu M; Aguele C; Darr U
Clin Case Rep; 2017 May; 5(5):636-639. PubMed ID: 28469866
[TBL] [Abstract][Full Text] [Related]
15. Effect of chamomile intake on blood coagulation tests in healthy volunteers: a randomized, placebo-controlled, crossover trial.
Schwartz JA; Romeiser JL; Kimura R; Senzel L; Galanakis D; Halper D; Mena S; Bennett-Guerrero E
Perioper Med (Lond); 2023 Sep; 12(1):51. PubMed ID: 37730613
[TBL] [Abstract][Full Text] [Related]
16. Activated charcoal helps in the diagnosis of dabigatran overdose: A case study.
Zhang N; Niu W; Zhang H; Lu S
Int J Clin Pharmacol Ther; 2024 May; ():. PubMed ID: 38726562
[TBL] [Abstract][Full Text] [Related]
17. Conservative management of massive rivaroxaban overdose: A case report and literature review.
Ghodsi A; Etemad L; Dadpour B; Mostafazadeh B; Moshiri M
Clin Case Rep; 2021 Nov; 9(11):e05023. PubMed ID: 34765205
[TBL] [Abstract][Full Text] [Related]
18. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
Levi M; Moore KT; Castillejos CF; Kubitza D; Berkowitz SD; Goldhaber SZ; Raghoebar M; Patel MR; Weitz JI; Levy JH
J Thromb Haemost; 2014 Sep; 12(9):1428-36. PubMed ID: 24811969
[TBL] [Abstract][Full Text] [Related]
20. Idarucizumab for Dabigatran Reversal.
Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
